Phase 1, Phase 2RecruitingPriority 2 · High priorityNCT05589896
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Plain-language summary
This Phase 1, Phase 2 trial is studying Ossium HPC Marrow, Bone Marrow Transplant, and other medications for people with cutaneous T-cell lymphoma (skin lymphoma). Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 9 US locations across multiple states.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Ossium HPC Marrow, Bone Marrow Transplant (OTHER): Hematopoetic Cell Transplantation | Pre-transplant conditioning - Myeloablative (MAC) (OTHER): Regimen A or Regimen B | Pre-transplant conditioning - Reduced Intensity (RIC) (OTHER): Regimen C or Regimen D | Post-transplant treatment (OTHER): Post-transplant treatment
- Drugs / treatments
- Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC), Post-transplant treatment
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details